Cue Biopharma Statistics
Share Statistics
Cue Biopharma has 75.35M
shares outstanding. The number of shares has increased by 30.23%
in one year.
| Shares Outstanding | 75.35M |
| Shares Change (YoY) | 30.23% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 22.95% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 7,776 |
| FTD / Avg. Volume | 4.57% |
Short Selling Information
The latest short interest is 867.05K, so 1.15% of the outstanding
shares have been sold short.
| Short Interest | 867.05K |
| Short % of Shares Out | 1.15% |
| Short % of Float | 1.15% |
| Short Ratio (days to cover) | 6.31 |
Valuation Ratios
The PE ratio is -1.51 and the forward
PE ratio is -1.86.
Cue Biopharma's PEG ratio is
0.04.
| PE Ratio | -1.51 |
| Forward PE | -1.86 |
| PS Ratio | 6.61 |
| Forward PS | 1.2 |
| PB Ratio | 3.51 |
| P/FCF Ratio | -1.69 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Cue Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.84,
with a Debt / Equity ratio of 0.51.
| Current Ratio | 1.84 |
| Quick Ratio | 1.84 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | -0.21 |
| Debt / FCF | -0.24 |
| Interest Coverage | -52.14 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $226,512.2 |
| Profits Per Employee | $-992,048.78 |
| Employee Count | 41 |
| Asset Turnover | 0.29 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -54.27% in the
last 52 weeks. The beta is 1.51, so Cue Biopharma's
price volatility has been higher than the market average.
| Beta | 1.51 |
| 52-Week Price Change | -54.27% |
| 50-Day Moving Average | 0.85 |
| 200-Day Moving Average | 1.04 |
| Relative Strength Index (RSI) | 42.02 |
| Average Volume (20 Days) | 170,030 |
Income Statement
In the last 12 months, Cue Biopharma had revenue of 9.29M
and earned -40.67M
in profits. Earnings per share was -0.72.
| Revenue | 9.29M |
| Gross Profit | 6.94M |
| Operating Income | -41.5M |
| Net Income | -40.67M |
| EBITDA | -41.5M |
| EBIT | -41.47M |
| Earnings Per Share (EPS) | -0.72 |
Full Income StatementBalance Sheet
The company has 22.46M in cash and 8.88M in
debt, giving a net cash position of 13.58M.
| Cash & Cash Equivalents | 22.46M |
| Total Debt | 8.88M |
| Net Cash | 13.58M |
| Retained Earnings | -341.86M |
| Total Assets | 32.19M |
| Working Capital | 11.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -36.33M
and capital expenditures -66K, giving a free cash flow of -36.4M.
| Operating Cash Flow | -36.33M |
| Capital Expenditures | -66K |
| Free Cash Flow | -36.4M |
| FCF Per Share | -0.65 |
Full Cash Flow StatementMargins
Gross margin is 74.7%, with operating and profit margins of -446.86% and -437.97%.
| Gross Margin | 74.7% |
| Operating Margin | -446.86% |
| Pretax Margin | -437.97% |
| Profit Margin | -437.97% |
| EBITDA Margin | -446.86% |
| EBIT Margin | -446.86% |
| FCF Margin | -391.89% |
